---
type: Person
title: Ashley Sanders
description: Person appearing in 120 documents.
tags:
  - person
  - nih
organization: nih
document_count: 120
first_seen: "2020-05-13T11:59:00"
last_seen: "2020-09-11T16:21:38"
aliases:
  - Ashley Sanders
sources:
  - { id: reading_room, resource: /sources/reading-room.md, title: Reading Room Production, author: "process:senate-hsgac-release" }
generated: { by: randpaul-corpus-pipeline/1.0, at: "2026-08-01T12:42:27Z" }
status: stable
---

Appears in the COVID-19 subpoena corpus.

# Activity

- **Documents:** 120 (sent/authored 66, received 54)
- **Active:** 2020-05-13 to 2020-09-11
- **Organization:** [nih](/organizations/nih.md)

# Correspondents

| Person | Messages | First | Last |
|---|---:|---|---|
| [Emily Linde](/people/emily-linde.md) | 90 | 2020-05-13 | 2020-09-10 |
| [Mike Shannon](/people/mike-shannon.md) | 56 | 2020-05-13 | 2020-09-10 |
| [Erik Stemmy](/people/erik-stemmy.md) | 38 | 2020-05-21 | 2020-05-22 |
| [Deborah Kearse](/people/deborah-kearse.md) | 14 | 2020-09-09 | 2020-09-10 |
| [David A Miller](/people/david-a-miller.md) | 4 | 2020-05-22 | 2020-05-22 |
| [Michael Lauer](/people/michael-lauer.md) | 4 | 2020-09-11 | 2020-09-11 |
| Deborah | 1 | 2020-09-11 | 2020-09-11 |
| Deborah | 1 | 2020-09-11 | 2020-09-11 |
| Emily | 1 | 2020-05-22 | 2020-05-22 |
| Emily | 1 | 2020-05-22 | 2020-05-22 |
| Erik | 1 | 2020-05-22 | 2020-05-22 |
| Erik | 1 | 2020-05-22 | 2020-05-22 |
| Erik | 1 | 2020-05-22 | 2020-05-22 |
| Erik | 1 | 2020-05-22 | 2020-05-22 |
| Erik | 1 | 2020-05-22 | 2020-05-22 |

# Topics

* [EcoHealth Alliance funding and grants](/topics/ecohealth-funding.md) - 120 documents
* [Intelligence community assessments](/topics/intelligence-community.md) - 108 documents
* [Awards, honoraria and recognition](/topics/awards-honoraria.md) - 60 documents
* [Gain-of-function research](/topics/gain-of-function.md) - 40 documents
* [Lab-leak / accidental release hypothesis](/topics/lab-leak-origin.md) - 28 documents
* [Wuhan Institute of Virology collaboration](/topics/wiv-collaboration.md) - 28 documents
* [Gates Foundation involvement](/topics/gates-foundation.md) - 18 documents
* [Congressional oversight](/topics/congressional-oversight.md) - 14 documents
* [Furin cleavage site and molecular features](/topics/molecular-features.md) - 12 documents

# Statement timeline

What this person is recorded saying, in date order, quoted verbatim with page citations.

* **2020-05-13** ([gain_of_function](/topics/gain-of-function.md), asserts): "On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV." [^reading_room]
* **2020-05-13** ([wiv_collaboration](/topics/wiv-collaboration.md), asserts): "From a review of their experimental details, it looks as if they were generating recombinant DNA of the viruses using WIV1 as the backbone but I could not determine if they were using Seemless Cloning techniques." [^reading_room]
* **2020-05-13** ([gain_of_function](/topics/gain-of-function.md), asserts): "I could not determine exactly where they were conducting these gain of function experiments." [^reading_room]
* **2020-05-13** ([wiv_collaboration](/topics/wiv-collaboration.md), asserts): "On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states that humanized mouse in vivo experiments in humanized mice was occurring at the Wuhan Institute of Virology." [^reading_room]
* **2020-05-13** ([gain_of_function](/topics/gain-of-function.md), questions): "I did not see the location where these gain of function experiments were being done but if the injections were occurring at WIV then was the recombinant DNA also generated at WIV?" [^reading_room]
* **2020-05-20** ([intelligence_community](/topics/intelligence-community.md), asserts): "Good afternoon, We are following up on a time-sensitive request for information from the FBI." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "There may be some misunderstanding of gain-of-function experiments, so hopefully this will clarify some things or at least provide a framework for our discussion next week." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "The funding pause on gain-of-function (GoF) experiments was in place from 2014-2017, and explicitly involved work reasonably anticipated to enhance the transmissibility or pathogenicity of influenza, MERS-CoV, or SARS-CoV." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "The replacement policy, Potential Pandemic Pathogen Care and Oversight (P3CO), requires additional review and oversight of experiments that are anticipated to increase a potential pandemic pathogen's transmissibility or pathogenicity in humans." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "I could not determine exactly where they were conducting these gain of function experiments." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "I believe UNC mean to say that the work "... does not include human research subjects." SF 424 AI110964-01 (received date 06/05/2013) In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that exact…" [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "The receipt date of this application was June of 2013, and the term "gain-of-function" was not widely used before the USG funding pause was announced in 2014." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "The funding pause on gain-of-function (GoF) experiments was in place from 2014-2017, and explicitly involved work reasonably anticipated to enhance the transmissibility or pathogenicity of influenza, MERS-CoV, or SARS-CoV." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "The replacement policy, Potential Pandemic Pathogen Care and Oversight (P3CO), requires additional review and oversight of experiments that are anticipated to increase a potential pandemic pathogen's transmissibility or pathogenicity in humans." [^reading_room]
* **2020-05-22** ([wiv_collaboration](/topics/wiv-collaboration.md), asserts): "From a review of their experimental details, it looks as if they were generating recombinant DNA of the viruses using WIV1 as the backbone but I could not determine if they were using Seemless Cloning techniques." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "I could not determine exactly where they were conducting these gain of function experiments." [^reading_room]
* **2020-05-22** ([wiv_collaboration](/topics/wiv-collaboration.md), asserts): "This award did not support work to manipulate CoV genomes or create chimeric viruses at Wuhan Institute of Virology; such work was performed at UNC-CH." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "I believe UNC mean to say that the work "... does not include human research subjects." SF 424 AI110964-01 (received date 06/05/2013) In this SF 424 Aim 3 seems indicative of gain of function experimentation (C3a and C3b) although it does not use that exact…" [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "The receipt date of this application was June of 2013, and the term "gain-of-function" was not widely used before the USG funding pause was announced in 2014." [^reading_room]
* **2020-05-22** ([wiv_collaboration](/topics/wiv-collaboration.md), asserts): "On page 119 of AI110964-01 under "C3d) Humanized mouse in vivo infection experiments" it states that humanized mouse in vivo experiments in humanized mice was occurring at the Wuhan Institute of Virology." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), questions): "I did not see the location where these gain of function experiments were being done but if the injections were occurring at WIV then was the recombinant DNA also generated at WIV?" [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "Further, the USG P3CO Policy Guidance states that "Wild-type pathogens that are circulating in or have been recovered from nature are not enhanced PPPs, regardless of their pandemic potential." RPPR (AI110964-05) Finally, in the RPPR (6/1/2017-5/31/2018) on…" [^reading_room]
* **2020-05-22** ([wiv_collaboration](/topics/wiv-collaboration.md), asserts): "The figure you reference (Fig 35) shows weight loss and lung viral titers of chimeric viruses with bat CoV (wild type WIV-1, SHC014, WIV16, and 4231) spike proteins expressed on the WIV-1 backbone." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "There may be some misunderstanding of gain-of-function experiments, so hopefully this will clarify some things or at least provide a framework for our discussion next week." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "On page 192 of SF 424 AI110964-06 (received date 11/05/2018) under P3CO Research, it indicates they are conducting gain of function of SARSr-CoV." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "The funding pause on gain-of-function (GoF) experiments was in place from 2014-2017, and explicitly involved work reasonably anticipated to enhance the transmissibility or pathogenicity of influenza, MERS-CoV, or SARS-CoV." [^reading_room]
* **2020-05-22** ([gain_of_function](/topics/gain-of-function.md), asserts): "The replacement policy, Potential Pandemic Pathogen Care and Oversight (P3CO), requires additional review and oversight of experiments that are anticipated to increase a potential pandemic pathogen's transmissibility or pathogenicity in humans." [^reading_room]
* **2020-09-09** ([ecohealth_funding](/topics/ecohealth-funding.md), acknowledges): "In a recent discussion with HHS OIG and the FBI, they noted they received information that the below-grant with Ecohealth Alliance was "suspended" or "terminated"." [^reading_room]

# Sources

[^reading_room]: [reading_room](/sources/reading-room.md)